EGFR Biomarkers
News and reporting on EGFR biomarkers.
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.
European Commission Approves J&J's Subcutaneous Rybrevant for Certain NSCLC Patients
The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.
Vividion Begins Phase I Trial of RAS-PI3Kα Inhibitor in Advanced Solid Tumors
The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.
CHMP Recommends Approval of J&J's Subcutaneous Rybrevant for Certain NSCLC Patients in Europe
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
Nov 19, 2024
Sep 27, 2024